The comparative study of single-use of ATO or ATO combined with ATRA in the treatment of primary acute promyelocytic leukemia
WANG Yufang
KE Jinyong
Abstract：Objective To investigate the therapeutic effects and safety of single -use of arsenic trioxide ( ATO) or ATO combined with all -trans retinoic acid ( ATRA) on primary acute promyelocytic leukemia .Methods One hundred and fifty patients with primary acute promyelocytic leukemia who were admitted and treated in our hospital from March 2010 to March 2013 were randomly divided into two groups:control group ( n =75) and combination treatment group ( n =75).The patients in control group were treated by ATO only , however , the patients in combination treatment group , on the basis of control group,were treated by ATRA.The complete remission rate,the time of reaching complete remission ,early death rate, follow-up survival rate ,incidence rates of toxic and side effects , liver function , levels of myocardial enzymes and blood lipid indexes after treatment were observed and compared between two groups .Results There was no significant difference in complete remission rate between two groups ( P >0.05).The time of reaching complete remission in combination treatment group was significant shorter than that in control group ( P <0.05).There were no significant differences in early death rates and survival rate after 1-year follow up between two groups ( P >0.05 ).The survival rates after 3-year follow up in combination treatment group were significant higher than those in control group ( P <0.05 ).There were no significant differences in incidence rates of toxic and side effects between two groups ( P >0.05).After treatment the levels of liver function indexes in combination group were significant higher than those in control group ( P <0.05).The levels of myocardial enzymes in combination treatment group were significant lower than those in control group ( P <0.05).There were no significant differences in the levels of blood lipid indexes between two groups ( P >0.05).Conclusion The ATO combined with ATRA in the treatment of primary acute promyelocytic leukemia can effectively shorten the time of reaching complete remission , improve the long-term survival rate , moreover , which does not increase the incidence rate of adverse reactions .
Keywords：arsenic trioxideall-trans retinoic acidcute promyelocytic leukemiatherapeutic effectssafety
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 37-39 )